Ferguson Lecturer to Discuss Cancer Immunotherapy

Thomas B. Ferguson Lecture: Cancer Immunotherapy: The End of the Beginning


3:30 p.m. – 4:30 p.m.

Ballroom 20

The first of the exciting keynote lectures at the STS Annual Meeting—the Thomas B. Ferguson Lecture on Sunday afternoon—will feature Laurie H. Glimcher, MD, who has made seminal discoveries in cancer immunology research, particularly in the fields of transcriptional regulation, lymphocyte differentiation, immunology, and osteobiology. She is President and CEO of the Dana-Farber Cancer Institute, Principal Investigator and Director of the Dana-Farber/Harvard Cancer Center in Boston, and the Richard and Susan Smith Professor of Medicine at Harvard Medical School. Her address is titled “Cancer Immunotherapy: The End of the Beginning.”

Laurie H. Glimcher, MD

Laurie H. Glimcher, MD

Dr. Glimcher will discuss the history and current state of cancer therapy and present active areas of innovation such as cancer genomics, immunotherapy, epigenetics, and approaches to combination therapy. She also will provide her vision for the long-term future of cancer treatment and prevention, including efforts for earlier detection of minimal residual disease and relapse by measuring circulating tumor DNA and using machine learning/artificial intelligence.

The Ferguson lecture recognizes Thomas B. Ferguson, MD, a former editor of The Annals of Thoracic Surgery and one of the few individuals to serve as President of both STS and the American Association for Thoracic Surgery.